Trigger Alert: Jupiter Endovascular Series B

🚀 Battle Card: Jupiter Endovascular

• Carl St. Bernard, CEO 📧 <carl@jupiterendo.com>

• This Jupiter Endovascular sales trigger signals a shift from R&D to go-to-market acceleration. → Source

• Completing SPIRARE II pivotal clinical trial under time pressure

• Building commercialization infrastructure amid regulatory complexity

• Primary: Clinical trial management platform → Accelerate trial milestones and reporting

• Expansion: Commercial launch enablement services → Streamline market entry and partnerships

• HQ: Menlo Park, CA

• Employees: ≈ 50

• Rev: ≈ $0.5 M (pre-commercial)

• Website: [jupiterendo.com](https://jupiterendo.com)

🤼 Competitive Intel

• Salesforce — CRM
• Unique edge: End-to-end sales analytics
• Evaluated by: VP Sales & CFO

• HubSpot — CRM & Sales Automation
• Unique edge: Integrated marketing & sales platform
• Evaluated by: Dir. Marketing & VP Ops

• Outreach — Sales Engagement
• Unique edge: AI-driven cadences
• Evaluated by: Sales Ops & AE teams

• Marketo — Marketing Automation
• Unique edge: Robust lead nurturing
• Evaluated by: CMO & Dir. Marketing

• Mailchimp — Email Marketing
• Unique edge: User-friendly campaigns
• Evaluated by: Marketing Manager

• Pardot — B2B Marketing
• Unique edge: Salesforce integration
• Evaluated by: VP Marketing & IT

• Atlassian Jira — Project Tracking
• Unique edge: Agile boards & reporting
• Evaluated by: CTO & Product Lead

• GitHub — Code Collaboration
• Unique edge: DevOps integrations
• Evaluated by: Dev Team & CTO

• Slack — Team Collaboration
• Unique edge: Channel-based comms
• Evaluated by: All Engineering Teams

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑clinical trial management platform❑
PROOF_METRIC  = ❑≈ TBD❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Carl
COMPANY     = Jupiter Endovascular
DEPT        = Executive
SIZE        = 50
BOTTLENECK  = Completing SPIRARE II pivotal clinical trial under time pressure
EVENT       = Completes Series B Round
DETAIL      = Series B financing oversubscribed, surpassed $40M
PAIN        = Building commercialization infrastructure amid regulatory complexity
SRC         = https://vcnewsdaily.com/jupiter-endovascular/venture-capital-funding/yywyrzhbvm
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈50
REV_EST     = ≈$0.5M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: 50-person Executive

Carl—noticed your Executive team is ≈ 50.

That’s when Completing SPIRARE II pivotal clinical trial under time pressure slows growth.

We helped ≈ TBD fix this with clinical trial management platform.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about Series B financing oversubscribed, surpassed $40M — Building commercialization infrastructure amid regulatory complexity.  
clinical trial management platform. ≈ TBD.  
Quick chat?